Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schiff

Showing results (211-220 of 305) with videos related to

Pageof 31
Sort By:
Neuro-Oncology|June 26, 2021
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumorsTobias Walbert, Rebecca A Harrison, David Schiff, et al.
Neuro-Oncology|April 24, 2016
Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cellsPítia F Ledur, Chong Liu, Hua He, et al.
Neuroradiology|December 17, 2013
Multimodal MR imaging model to predict tumor infiltration in patients with gliomasChristopher R Durst, Prashant Raghavan, Mark E Shaffrey, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Cancer|January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2018
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in GlioblastomaNichola Cruickshanks, Ying Zhang, Sarah Hine, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Cancer Research|May 18, 2017
Targetable T-type Calcium Channels Drive GlioblastomaYing Zhang, Nichola Cruickshanks, Fang Yuan, et al.
Pageof 31

Showing results (211-220 of 305) with videos related to

Sort By:
Pageof 31
Neuro-Oncology|June 26, 2021
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumorsTobias Walbert, Rebecca A Harrison, David Schiff, et al.
Neuro-Oncology|April 24, 2016
Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cellsPítia F Ledur, Chong Liu, Hua He, et al.
Neuroradiology|December 17, 2013
Multimodal MR imaging model to predict tumor infiltration in patients with gliomasChristopher R Durst, Prashant Raghavan, Mark E Shaffrey, et al.
Investigational New Drugs|July 14, 2005
Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeSusan M Chang, Patrick Wen, Timothy Cloughesy, et al.
Cancer|January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2018
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in GlioblastomaNichola Cruickshanks, Ying Zhang, Sarah Hine, et al.
Cancer|December 22, 2017
Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastomaDavid A Reardon, Andrew B Lassman, David Schiff, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Cancer Research|May 18, 2017
Targetable T-type Calcium Channels Drive GlioblastomaYing Zhang, Nichola Cruickshanks, Fang Yuan, et al.
Pageof 31